University of South Carolina

Scholar Commons
Theses and Dissertations
Summer 2021

Characterization of pH – Responsive Nanocage Based on the
Ferritin Iron Storage Protein
Satyam Singh

Follow this and additional works at: https://scholarcommons.sc.edu/etd
Part of the Biochemistry Commons, and the Chemistry Commons

Recommended Citation
Singh, S.(2021). Characterization of pH – Responsive Nanocage Based on the Ferritin Iron Storage
Protein. (Master's thesis). Retrieved from https://scholarcommons.sc.edu/etd/6425

This Open Access Thesis is brought to you by Scholar Commons. It has been accepted for inclusion in Theses and
Dissertations by an authorized administrator of Scholar Commons. For more information, please contact
dillarda@mailbox.sc.edu.

Characterization Of pH – Responsive Nanocage Based on The Ferritin Iron
Storage Protein
By
Satyam Singh
Bachelor of Technology
Jaypee University of Information Technology, 2018

Submitted in Partial Fulfillment of the Requirements
For the Degree of Master of Science in
Chemistry and Biochemistry
College of Arts and Science
University of South Carolina
Accepted by:
F. Wayne Outten, Director of Thesis
M. Chruszcz, Reader
Tracey L. Weldon, Interim Vice Provost and Dean of the Graduate School

© Copyright by Satyam Singh, 2021
All Rights Reserved

ii

DEDICATION
It is with genuine gratefulness and warmest regard that I dedicate this work to my
parents, Arun K Singh. and Ritaja Singh, my brother Shubham Singh, and sister-in-law
Shubha Singh, who made incessant sacrifices supporting my highest hopes and praising
my smallest successes. Secondly, I dedicate this work to my cousin sister and my mentor
Pragya Singh, who guided me in my most difficult moments. Thirdly, I dedicate this work
to my lab friends Dr. Angela-Nadia Albetel, Claire Fisher, David Eap, Alison Kimsey,
Evan A Talib, Terrell Carter, Prajwal Patel, Leily Daneshian, and Anyway B. Kapingidza
to make each moment spent in lab joyful when research was stressful. Finally, I dedicate
this work to my best friends, Amit Bhandari, Rishabh Nautiyal and Kritika Sharma for
keeping me sane throughout this arduous journey and being my companion through many
long nights of writing!

iii

ACKNOWLEDGEMENTS
I hereby acknowledge with deep gratitude, the cooperation and help given by all
members of Biochemistry department in helping with my project. With proud privilege and
profound sense of gratitude, I acknowledge my indebtedness to my guide Dr. F. Wayne
Outten for valuable guidance, suggestions, constant encouragement and cooperation. I
would like to extend my deep and sincere gratitude to my thesis committee, Dr. M.
Chruszcz, Dr, C. Tang and Dr. R. Patel.
Last but not the least I place a deep sense of gratitude to my family members and
my friends who have been constant source of inspiration during the preparation of this
project work.

iv

ABSTRACT
The iron-storage protein ferritin (Ftn) assembles into a protein cage structure with
24 subunits and octahedral (4-fold, 3-fold, 2-fold) symmetry. Each monomeric subunit
contains a robust four-helix bundle fold. The fully assembled Ftn structure has a high
degree of thermal stability (up to 100°C), a mono dispersed size (12 nm in diameter), and
a large central cavity (7-8 nm in diameter). The central cavity stores ferric iron in
phylogenetically diverse group of organisms, including humans. The central cavity has
been used for encapsulation of cargoes such as other metals, contrast agents for imaging,
small molecule drugs for therapy, as well as smaller nanoparticles. Ferritin has been widely
used for several biomaterials, ranging from nanostructured composite materials to
semiconductors to imaging reagents due to its attractive properties. Here we describe our
initial efforts to design, generate, and test a series of pH-responsive derivatives of Ferritin
(Ftn) protein nanocages that are competent for drug delivery through the endocytic
pathway and may be helpful as responsive scaffolds for biomaterials construction. We plan
to use a combination of analytical, biochemical, and biophysical techniques to characterize
the Ftn derivates, thereby providing new insight into the principles for engineering biomacromolecular assemblies for stimuli responsiveness.
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CHAPTER 1: INTRODUCTION
Currently the commonly used drug delivery methods are oral consumption of pills
and liquid medicines, intravenous injections, nasal and respiratory inhalation, and the
topical or dermal application of ointments and creams. The basis of these methods is
systemic release of drug all over the body which causes lower bioavailability at the target.
To successfully circulate and release of drug at the target there have been surge in research
and development of smart drug delivery systems (DDS).1 Nanomaterial based DDS has
been developed in past with great therapeutic efficacy.2, 3 Despite great efficacy, these
nanoparticles are accompanied with many disadvantages like they are not biocompatible
and biodegradable that could cause cell toxicity.4 Moreover, for internalization of these
nanoparticles chemical derivatization is required.5,6 Nanoparticles based on biological
molecules can be perfect for DDS as they will be biocompatible and biodegradable.7- 9
For normal function of cells, constant flow of nutrients and waste is required. This
process of flow, through specialized pathways known as membrane trafficking pathway,
controls important cellular activities.10 This pathway can be divided into two basic
pathways called endocytosis and exocytosis. Endocytosis (Figure 1.1) is a mechanism to
internalize and transport macromolecules using endosomal scaffold vesicles (endosomes).
Lysosomes which are the last form endosomes have pH 5.5 – 6.0, is the most important
feature which can be used for drug release at the target. In this project we are focusing on
receptor mediated internalization using endocytic pathway of novel drug delivery system
1

that has the ability to use the change in pH property when internalized by an endosome in
a cell.11
Ferritin, a ubiquitous protein used for intracellular iron storage and release, is an
exciting candidate for use in drug delivery. Ferritin is an oligomer protein comprised of 24
subunits, which are a heterogeneous combination of H (heavy) and/or L (light) chains and
octahedral (4- fold, 3-fold, 2-fold) symmetry. Each subunit consists of five α-helices (AE) and an extended loop (BC loop). The fully assembled Ftn (Figure 1.2) structure has a
high degree of thermal stability (up to 100°C), a small and mono dispersed size (12 nm in
diameter), and a large central cavity (7-8 nm in diameter). The central cavity (Figure 1.3)
has also been used for encapsulation of cargoes such as other metals, contrast agents for
imaging, small molecule drugs for therapy, as well as smaller nanoparticles.12-14 Human
ferritin heavy (hFtnH) and light (hFtnL) chains are expressed in many cell types through
the body as well as in the extracellular space and circulating plasma. Human Ferritin is,
therefore, biocompatible, and likely to be nonimmunogenic (depending on the extent of
modification). Unmodified hFtn nanocages can enter cells through receptor-mediated
endocytosis using native cell surface receptors such as transferrin receptor 1 (Tf1) and the
scavenger receptor Scara5.15 Non-immunogenicity of ferritin provides one of the main
reason to choose it for this project. On the other hand, surface derivatization of Ftn, either
by chemical ligand-conjugation or genetic modification, can be used to target Ftn to nonnative receptors or other cell targets selectively.13
There have been many previous literatures published on application of other caged
protein which can be modulated by pH change.16 - 20 Viral nanocages, Norwalk capsids or
Cowpea Chlorotic Mottle Virus can assemble at low pH and disassemble at high pH. 16-18
2

However, in case of ferritin this property is totally opposite. It remains assembled at very
high ranged of pH 21 and disassembles in very high acidic pH solution.20,22 Native human
Light Chain Ferritin can disassemble in very harsh acidic conditions (pH ~2.0 - 3.0), which
is not favorable for many drugs.23 There have been no reports published that mentions any
nanocage protein which has the ability to assemble and disassemble near physiological pH.
Many have hypothesized that interactions that causes assembly and disassembly of
these nanocage protein can be controlled by modifying sequences responsible for
interactions24. Based on this hypothesis, N-terminal modification was tested to alter viral
capsids assembling ability, which caused decrease in volume of nanocage.17,25 Similar
modification was applied on dihydrolipoamide acetyltransferase by Wang and coworkers
which resulted in successful disassembling at pH 5.26,27 According to the published
structures by Wang group of light chain ferritin, it lacks N-terminal embracing arm which
was important for assembling of other cage proteins.21 So this makes it impossible to apply
the approach of deleting N-terminal arm (Figure 1. 4) to induce pH responsive switching
in human light chain ferritin. However, similar approach was applied on human heavy
chain ferritin in which 13 residues from N-terminal of E-helix was deleted. This approach
failed in stopping reassembling at pH 5.19 Other approaches like substituting amino acid
residues in hydrophilic channel of four helix bundle were also reported but similar results
were observed.20 All these approaches mentioned in previous literatures confirm that
deleting or substituting amino acid in A, B, C, and D helices will not cause ferritin to
disassemble at pH 5. To increase pH responsive switching in ferritin, peptide sequences
that have been developed for the application of drug delivery by pH variation will be used
in this project.28 - 30 Previous study concluded that 13 H-chain variants were less stable as
3

compared to L-chain variants in denaturing condition so, we decided to use L-chain ferritin
homopolymer for this project.20
In this study, E. coli BL21 DE3 is used as model organism for its ability of high
expression.31 The significant time in this project was used to design a protein that can have
a high yield and is adequately folded in 24-mer form when in buffered solution at
physiological pH. To date, hFtnL-E4 has been purified using the process defined in
appendix. Now further disassembling and assembling of the protein will be analyzed using
size exclusion chromatography (SEC), Circular Dichroism (CD) spectra, and Isothermal
Titration Calorimetry (ITC).32

- 44

Later on, protein nanocage will be loaded with

doxorubicin- Cu(II), and the structure of unloaded and loaded hFtnL-E4 will be analyzed
using static light scattering (SLS), SAXS, TEM, and X-ray crystallography.
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Figure 1.1 Pathway for molecule Internalization.
In eukaryotic cells, membrane trafficking is divided into two major pathways. In
endocytosis, proteins are internalized from the outer cell surface into the early
endosomes. The early endosome determines the trafficking route for the internalized
material.
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A

C

B

Figure 1.2 Human light chain Ferritin structure depicted using PyMol.
A) 24-mer form showing channel formed by E-helices at the center. B) Antiparallel
alignment of protein monomers. C) 4-Fold axis alignment at the channel.
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Figure 1.3 Horse spleen light chain ferritin.
Horse spleen light chain ferritin complexed with carboplatin (PDB code: 5mij) with 24
helical protein subunits shown in blue, Cd in orange, and Pt in silver. Top, ribbon view of
structure. Middle, surface representation of structure. Bottom, partial cut-away of
structure showing interior cavity.
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Figure 1.4 Monomer of Human Light chain Ferritin showing N-terminal and Cterminal arm.
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CHAPTER 2: STRUCTURAL CHARACTERIZATION OF hFtnL-GALA6
2.1 BACKGROUND AND INTRODUCTION OF hFtnL-GALA6
The GALA peptide consists of the core amino acid sequence Glu-Ala-Leu-Ala
repeated up to 7 times in series. Under neutral pH conditions (>pH=7.0), this sequence
adopts a random coil structure, but when the pH is shifted to mildly acidic (pH=5.0), the
amino acids assemble into an a-helix.23, 21 It was previously shown that the native E-helix
of hFtnL could be replaced with a peptide of repeating Glu-Ala-Glu-Ala ("GALA") units,
without significantly altering the assembly of the Ftn 24-subunit nanocage at pH=7.0
(Figure 2.1).28 Depending on the number of GALA repeats that are inserted, when the
hFtnL-GALA nanocages are shifted to pH<6.0, the coil-helix (Figure 2.2) transition in the
GALA peptide causes disassembly of the nanocage into smaller subunits, presumably by
disrupting monomer-monomer interactions at the 4-fold symmetry axis within the
nanocage (Figure 2.3). The greater pH-responsiveness of hFtnL-GALA make it more
useful as a biomaterial, especially for disassembly and delivery of cargo in the pH range
4.5 - 5.0 of the lysosome within the endosomal pathway.29, 30 Although the hFtnL-GALA
was

partially

characterized

in

vitro,

the

assembly/disassembly

kinetics

and

thermodynamics have not been carefully analyzed, nor has it been structurally
characterized beyond examining the oligomeric state in solution.28 There are no published
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attempts to load this pH-responsive nanocage with cargo, nor has the hFtnL-GALA6 been
directly tested for interactions with native cell receptors (such as Scara5).
Unexpectedly, the construct described in the literature did not express with high
yields of soluble protein, and the sample that was purified had limited solubility in the
absence of Imidazole and ultimately precipitated upon acidification below pH 7.28 These
complications limited the progress toward the goals using GALA6 repeats. However, two
main features were concluded from the evaluation of GALA. (1) Glu is the main driving
force for the random coil and α-helix formation. (2) The solubility issues originate from
the high hydrophobic content of the GALA peptide.
2.2 EXPRESSION AND PURIFICATION OF hFtnL-GALA6
Over the years there have been multiple attempts to purify light chain of ferritin.
The first time a modified pH-responsive hFtnL was expressed and purified was by Choi et
al. In that published work, a polyhistidine tag was inserted at the N-terminus of light chain
ferritin and the E-helix was replaced by six GALA repeats. E. coli BL21 (DE3) cells were
used for overexpression of hFtnL-GALA6 (MW – 21593.28 Da) and it was purified by
Immobilized Metal Affinity Chromatography (IMAC) using HisTrap FF 5 mL column
followed by Size Exclusion Chromatography (SEC). Overall net yield reported in the
previous paper was 1L in 2 mL protein solution.
In this research we first sought to reproduce the published pH-responsive ferritin as
a standard to compare against other modified ferritins. The E-helix of human light chain
ferritin was replaced with EALAEALAEALAEALAEALAEALAE (GALA6) and the
chimeric gene was cloned into the pET28a plasmid to fuse it to a six-histidine tag at the Nterminus of the protein. E. coli BL21 (DE3) containing the pET28a-hFtnL-GALA6 plasmid
10

was grown in one-liter of Luria-bertani (LB) cultures were grown to an OD600 of 0.8 and
induced with 200 μM isopropyl β-D-1-thiogalactopyranoside (IPTG), cooled to 20°C, and
grown overnight. Harvested cell pellet was resuspended in ice-cold lysis buffer (50 mM
Tris–HCl, pH 8.0, 100 mM sodium chloride, 1 mM phenylmethylsulfonyl fluoride) and
homogenized with an ultrasonic processor. Cells were lysed by sonication and lysate
(supernatant) was separated from lysed cell pellet by centrifuging at 20,000 ×g for 45 min.
Lysate was loaded on a HisTrap FF (Cytiva) 5 mL column equilibrated with 50 mM Tris–
HCl, pH 8.0, 100 mM sodium chloride, 20 mM imidazole. Bound proteins were eluted
using 50 mM Tris–HCl pH 8.0, 100 mM sodium chloride, 500 mM imidazole with linear
gradient method using 20 Column Volume (CV) solution. Extraction efficiency and
fractions containing hFtnL-GALA6 was assessed using 15% SDS-PAGE gel.
Chromatogram (Figure 2.4) from first purification showed multiple peaks however,
analysis of lysed cell pellet (CP), Lysate, Flowthrough (FT), fractions (19, 26, 36) proved
that all the hFtnL-GALA6 remained in the insoluble portion of the cell pellet. This could
be due to two reasons (1) formation of inclusion bodies or (2) poor protein extraction by
this method. Table 2.1 shows all the attempts to extract maximum protein from cells.
Lysis Buffer (50mM Tris pH 7.4, 300 mM NaCl, 1mM PMSF, 1mg/mL Lysozyme,
0.8% cholic acid) gave the best result for extraction of protein from the insoluble pellet
(Figure 2.5). However, following the IMAC purification step, the protein started
precipitating when total solution collected from fractions was decreased to 5 mL while
preparing 2 mL concentrated sample for SEC purification. Similar results were observed
after addition of 10 mM β-mercaptoethanol and 5% glycerol to the buffer. Sort of naively
thought that histidine tag might be causing aggregation of protein so we thought of
11

decreasing pH near to Histidine to pKa value so it might function as buffer and not cause
protein precipitation at higher concentration. Moreover, to facilitate this decrease in pH we
chose Sodium Phosphate buffer which has pH range of 5.8 – 8.0. So, we decreased pH to
6.5 and Tris to Sodium phosphate buffer. At this point concentration of 2 mL double
purified protein sample was 1mg/mL. this sample was used for Differential Scanning
Fluorimetry.
Monitoring changes in the thermal stability of a protein under different buffer
conditions can be used to identify buffer conditions that would favor higher solubility of
pure protein in solution. Thermal stability of hFtnL-GALA6 was screened under different
buffer ionic strength and pH conditions using differential scanning fluorimetry (DSF).45 A
Bio-Rad CFX96 RT-PCR instrument was used for DSF. A working concentration of 50
mM for the buffer was used for all the conditions with a pH range of 4.0−9.5 (in 0.5-unit
increments) and a salt range (sodium chloride) 0.15−1.15 M (0.15, 0.275, 0.40, 0.65, 0.775,
0.9, 1.025 and 1.15 M). Samples for DSF were prepared according to previously published
literature.13 The melting temperature (Tm) of hFtnL-GALA6 was determined in each
condition using Bio-Rad CFX Manager software. Average Tm was calculated by
performing the experiment three times.13, 28
The highest melting temperature that was determined for hFtnL-GALA6 was 56°C.
As shown in Table 2.2 (black box) it was found that buffers having pH 6.5-7.4 with NaCl
concentration 0.15-0.65 M are favorable for protein thermal stability. Considering the
results from DSF, we made 50 mM Sodium Phosphate buffers pH 7.4, 300 mM NaCl, 10
mM BME. We also tested addition of different concentrations of glycerol to the buffer.
We also attempted to decrease the formation of inclusion bodies during hFtnL-GALA6
12

expression in vivo. The chaperone plasmid pGKJE8 from Takara Bio was introduced into
the cells expressing hFtnL-GALA6. This plasmid expresses both the dnaK-dnaJ-grpE
chaperone system (under control of the araB promoter induced using 0.5mg/mL LArabinose) and the groES-groEL chaperone system (under control of the Pzt-1 promoter
induced using 5 ng/mL Tetracyclin). Having two promoters in plasmid provided the ability
to induce either or both protein folding chaperone systems. Even though amount of hFtnLGALA6 protein extracted from cell was increased after induction of both the chaperone
proteins from pGkJE8, which could be due to proper folding of hFtnL-GALA6, the hFtnLGALA6 protein still precipitated at concentrations above 1 mg/mL, making it difficult to
perform other downstream processes. So finally, cholic acid was maintained in all the
solutions during purification of hFtnL-GALA6.21
Table 2.3 shows the attempts that were done after DSF to get highest concentration
of protein solution. As for the final protocol, Lysis/Washing buffer (50 mM Sodium
Phosphate pH 7.4, 300 mM NaCl, 0.8% cholic acid, 2% glycerol, 10 mM BME, 20 mM
imidazole) was used for extraction and protein was eluted from Nickel column using
Elution Buffer (50 mM Sodium Phosphate pH 7.4, 300 mM NaCl, 0.8% cholic acid, 2%
glycerol, 10 mM BME, 500 mM imidazole). Eluted hFtnL-GALA6 was then concentrated
to 3.2 mg/L of cells in 2.4 mL with less precipitation and loaded onto Superdex 200 Hiload
16/60 prep grade column to separate the contaminants using SEC buffer (50 mM Sodium
Phosphate pH 7.4, 300 mM NaCl, 0.8% cholic acid, 2% glycerol, 10 mM BME). This also
removed imidazole from the solution. hFtnL-GALA6 was observed in two different peaks
(Figure 2.6 & 2.7) so, fractions from both peaks were collected and concentrated into one
sample. Overall yeild of protein after this purification was 2.6 mg/L of cells.
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2.3 MOLECULAR WEIGHT DETERMINATION USING SIZE EXCLUSION
CHROMATOGRAPHY
For the first characterization step for hFtnL-GALA6 the apparent solution molecular
weight was determined using an analytical grade superdex 200 10/300 GL column. Table
2.4 lists the standards, their molecular weights, and the concentrations that were used in
determining molecular weight of protein sample. Gel Filtration Markers kit was ordered
from Milipore Sigma for molecular weights 29,000 – 700,000 Da and Cytochrome C was
also ordered separately. The hFtnL-GALA6 sample that was in SEC buffer. So, this buffer
was used to make solutions of all the standards. Amount of standards were calculated for
100 µL sample and then all the standards were mixed separately first in 500 µL. These
standard solutions were mixed together and then concentrated to 100 µL. 100 µL Blue
dextran was prepared separately and then injected first in Superdex 10/300 gl column to
obtain Vo. Then 100 µL standard solution prepared was injected and eluted. Then 100 µL
of 2.6 mg/mL solution of hFtnL-GALA6 was injected on the column and then eluted.
Elution volume Ve of standards was obtained from the chromatogram. Since there were
multiple peaks observed in protein chromatogram so SDS-PAGE was used to detremine
the peaks that had hFtnL-GALA6. For standard curve, ratio of Ve/ Vo was plotted in
Microsoft Excel. Using the standard curve equation, the unknown molecular weight of
hFtnL-GALA6 was obtained. Since there were two peaks it can be infered from the
molecular weights that there are two forms of hFtnL-GALA6, a 24-mer and dimer. Figure
2.8 shows the overlapped chromatograms of standard and protein. Figure 2.9 and Table 2.5
shows the molecular weight calculation.

14

Ferritin has been proved to be a good nano-molecule that has the ability to store
molecules and is used for transportation. However, in previous attempts to load ferritin
buffer pH must be decreased to 2. This change in pH causes disassembling of protein. Most
of the drugs are unstable or degrade in acidic pH. To increase structure responsiveness
near neutral pH, the E-helix of human light chain Ferritin was replaced with six repeats of
GALA. This replacement was proved to increase the pH responsiveness in range pH 6.0 –
7.4 which was good for loading the nanocage. However, using leucine (L) in the GALA
sequence increased hydrophobicity of the protein and this may have caused overall yield
to be very low. It is possible to do sevral structural studies on this much low yield however,
using this protein industrially will not be very cost effective. Moreover, multiple peaks of
protein on analytical Superdex 200 10/300 GL column suggested that it was not properly
folded or have multiple forms even after adding so many additives. Whether the protein is
properly folded, or it is in dimer, trimer or tetramer form can only be confirmed using
Circular Dichroism Spectroscopy (CD spectra). However, these results from hFtnLGALA6 protein purification made it unsuitable to work any further.

15

Table 2.1 Attempts to solubilize hFtnL-GALA6.
Condition
Buffer
(50mM)

NaCl
pH
(mM)

Additives

8
100

Method

Observations

Sonication

•

No extraction

•

Extraction possible but
too much contamination

•

Extraction possible but
less contamination

None

7.5

Lysozyme,
Cholate, PMSF, •
Sonication
•

Tris-HCl
7.4

300

6.5
Sodium
Phosphate

10mM
BME, 5%
glycerol

•
•
•

Very less extraction,
more contamination,
protein
lost
Flowthrough

•

Very less extraction,
more
contaminated,
protein
lost
in
Flowthrough
during
Nickel column,
Concentration possible
but still aggregation,
Multiple peaks due to
contamination in SEC
purification,
Pure protein obtained
after SEC,
Concentrated to 1mg/ml

Dnase 1, MgCl2,
•
Lysozyme,
Cholate, PMSF,
•
Sonication
•
•

16

Better extraction,
zero
contamination,
unable to concentrate

in

Table 2.2 Differential Scanning Fluorimetry
This table shows the average temperature recorded after two experiments. Red color
shows very high temperature and blue color shows low temperature. T higher the
temperature, the more the protein is stable in that condition.
pH

4

4.5

5

5.5

6

6.5

7

7.5

8

8.5

9

9.5

56

49

54

50

53

56

55

38

30

30

30

30

0.275 48

51

60

52

51

55

56

53

43

35

30

51

0.4

48

59

54

53

54

55

55

54

54

54

35

35

0.65

48

51

54

53

54

56

54

43

54

30

31

31

0.775 48

51

55

53

55

42

55

42

47

30

35

38

0.9

50

51

49

48

54

43

42

54

31

31

36

32

1.025 39

42

41

50

38

35

30

31

32

32

32

32

1.15

46

49

46

46

46

46

39

49

46

46

32

0.15

NaCl
(mM)

39
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Table 2.3 Attempts to solubilize the hFtnL-GALA6

Plasmid

Condition
Buffer
NaCl
pH
Additives
(50mM)
(mM)

pET
28ahFtnLGALA6

Sodium
pET
28a- Phosphat 7.4 300
e
hFtnLGALA6
+
pGKJE8(Protei
n
Folding
Chaperone)

Method

Observations
•
•

10mM BME,
2%Glycerol

•

DNase 1,
•
MgCl2,
Lysozyme, •
•
Cholate,
PMSF,
10mM BME, Sonication •
10%Glycerol
10mM BME,
2%Glycerol,
0.8% Cholic
Acid
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•
•
•

No contamination,
still inclusion bodies are
formed,
concentrated till 1
mg/ml
Better extraction,
No contamination,
Concentrated till 1
mg/ml
Extraction hindered due
to
high
glycerol
concetration
Best extraction,
no contamination,
concentrated till 6
mg/ml

Table 2.4 Gel Filtration standards for molecular weight determination.
Standards

Molecular weight (kDa)

Concentration (mg/mL)

Thyroglobulin

660

5

Apo ferritin

440

0.4

Alcohol
Dehydrogenase

150

5

BSA

67

8

Ovalbumin

43

4

Cytochrome C

12

5

19

Table 2.5 Calculated molecular weight.

Standards

Molecular Weight
(kDa)

Ve (mL)

Ve/Vo

Thyroglobulin

669

8.8

1.13

Ferritin

474

10.99

1.42

Alcohol
Dehydrogenase

150

13.06

1.68

BSA

66

13.92

1.79

Oval albumin

45

14.8

1.91

Cytochrome C

12.3

17.33

2.23

Sample 1

540.2

9.57

1.23

Sample 2

72.9

15.07

1.94
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Figure 2.1 Coil to Helix transition of E-helix by changing pH.
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Figure 2.2 Monomer of Human light chain Ferritin and hFtnL-GALA.
α-helical secondary structure (cylinders) in hFtnL (top) and hFtnL-GALA (bottom). Helix
labels are per hFtnL nomencla
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Figure 2.3 Location where E-helix will cause disassembly.
Same 4 monomers magnified with the E-helix of each monomer shown in magenta as helix
and transparent surface representation. Other monomers not shown.
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hFtnL-GALA6

Figure 2.4 First attempt of purification. MW - 21593.28 Da
Protein extraction using Lysozyme Cholate method. Buffer Conditions : Lysis Buffer – 50mM Tris-HCL, 100mM NaCl pH 7.5. Wash Buffer
– 50mM Tris-HCl, 100mM NaCl, 20mM Imidazole pH 7.5. Elution
Buffer – 50mM Tris-HCl, 100mM NaCl, 500mM Imidazole pH 7.5.
[A] Chromatograph obtained after using HisTrap column. [B] Samples
observed on 15% SDS-PAGE.
24

%B

UV (AU)

Fraction

Volume (mL)

hFtnL-GALA6

Figure 2.5 Purification using HisTrap column showing increased extraction.
Protein extraction with pH 7.4. Buffer conditions -: Lysis/Washing Buffer – 50mM
Tris-HCl, 300mM NaCl, 20mM Imidazole, 10mM BME, 5% Glycerol. Elution Buffer
- 50mM Tris-HCl, 300mM NaCl, 500mM Imidazole, 10mM BME, 5% Glycerol. [A]
Chromatograph obtained after using His Trap column. [B] SDS- PAGE gel showing
fractions, lysate, and lysed cell (CP) after protein extraction.
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hFtnL-GALA6

Figure 2.6 SEC Chromatogram of final purification of hFtnL-GALA6
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hFtnL-GALA6

hFtnL-GALA6

Figure 2.7 15%SDS-PAGE gel showing hFtnL-GALA6 bands in fractions
from SEC purification.
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Figure 2.8 Molecular weight determination chromatogram
Overlapped chromatogram of standards and hFtnL-GALA6 protein solution.
Concentration of hFtnL-GALA6 is 0.4 mg/mL
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y = -659.31x + 1353.3
R² = 0.8731
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Figure 2.9 Standard curve for molecular weight determination.
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CHAPTER 3: STRUCTURAL CHARACTERIZATION OF hFtnL-E4
3.1 BACKGROUND
Working on hFtnL-GALA6 allowed us to understand the working of the EALA
sequence. In this peptide, Glutamate (E) was the primary driving force that would change
the E-helix structure to control disassembling and assembling of the protein. So moving
forward, we found another peptide sequence, EAQA, designed using Ensemble Allosteric
Model (EAM), and its efficiency to cause structural changes were analyzed by modifying
allosteric protein c4, which fuses maltose-binding protein (MBP) and TEM1 β-lactamase
(BLA).30 Initially using PyMol

46

, PHYRE2 47, and FATCAT
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we tried to estimate the

structure of EAQA modified hFtnL by completely replacing E-helix. Results of this
modification suggested the formation of the helix. However, analysis of WT-hFtnL
revealed that some of the amino acids of the E-chain were near other chains (A, B, C, D)
to form different types of interactions. These kinds of synergy suggested that the WThFtnL might be more stable and soluble to be produced in higher concentrations than
GALA modification.32 Comparing these data, we decided to mutate every fourth amino
acid with Glutamate in the E-helix of WT- hFtnL as well as to add the EAQA repeat on Cterminus to form an extended E-helix with four glutamate amino acid residues spaced
appropriately to form a pH-responsive helix similar in nature to GALA, but less
hydrophobic. Analysis of secondary structure using Pymol of the newly modified hFtnL,

30

produced using PHYRE2 to model the mutant structure, showed that E-chain amino acid
residues that might be interacting with other helices were not disturbed. Table 3.1
summarizes all the sequences that were tested. WT-hFtnL, hFtnL-E4, and hFtnL-E6 were
the proteins that were ordered after comparing GRAVY scores. Grand Average of
Hydropathicity index (GRAVY) indicates hydrophobicity of protein. GRAVY score below
0 are more hydrophilic protein. We hypothesized that the lower the GRAVY score, the
better would be the solubility. Due to the lack of any data available for new modifications
of Human Light Chain Ferritin, we decided to start from a small scale and increase it to
laboratory level large-scale production.
3.2 EXPRESSION AND PURIFICATION OF hFtnL-E4
The parent plasmid chosen was pET28a+. To form hFtnL-E4, pET28a+ was
digested using Ndel at 5’ end and Xhol at 3’ end and then the hFtnL-E4 sequence was
cloned into the plasmid. N-terminal of the protein is tagged with 6x Histidine for Nickel
affinity purification. E4 modification is present at the C-terminal. Similar method is applied
for hFtnL-E6. WT-hFtnL has no modification so it is simply cloned in pET28a+ using
above mentioned restricition enzyme with 6x Histidine tag at N-terminal.
Analyzing various sequences for hydrophobicity in comparison to hFtnL-GALA6,
hFtnL-E4 was found to be least hydrophobic. In this sequence instead of totally replacing
E-helix, every fourth amino acid of the native E-helix sequence was replaced with glutamic
acid (E). hFtnL – PEAGEGEYEFERETLKEAQAE (hFtnL-E4) was the sequence that
was analyzed first. There is no data available for this sequence so small-scale
overexpression analysis was performed. All three plasmids that were ordered, were
overexpressed at 37°C for 4h and 6h with IPTG of concentrations 0.1 mM, 0.25 mM, 0.5
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mM, 1 mM. B-per (thermo fisher) was used to lyse the cells. All the samples were sonicated
using a water bath sonicator for 15 min. Non-induced, induced, soluble protein solution
and lysed cell pellet were collected and observed on 15 % SDS-PAGE gel. Results (Figure
3.1 A & B) showed overexpression of proteins (hFtnL-WT, hFtnL-E4 and hFtnL-E6) but
there was no extraction as no band was observed near 25 kDa ladder. As all the modified
proteins were new except WT-hFtnL, we decided to troubleshoot expression of WT-hFtnL
so we could use that information to improve purification of other proteins. WT-hFtnL was
expressed in E. coli BL21 DE3 cells using pET28+ plasmid. This plasmid adds six
Histidine tag at the N-terminal of the protein. According to the literature on Histidinetagged WT-hFtnL, we decided to use 20°C to grow cells overnight.32 Protein
overexpression was induced using 1mM IPTG. For the proper folding of the protein and
decreasing formation of inclusion bodies, we added the pGKJE8 chaperone plasmid.32
Even though we were able to highly overexpress protein, during initial extraction using a
1x PBS buffer, the protein was degraded to form a thick dark band near 15 kDa. This can
be inferred from Figure 3.2 in which Induced non – lysed cells did not have any band at 15
kDa but lysed cells and soluble protein showed the band at 15 kDa as these samples were
subjected to sonication or lysis. Although this can only be confirmed by Mass
Spectrometry. However, since we still did not have any protein band near 25 kDa so, we
decided to analyze different parameters for the buffer and lysis method. While analyzing
suitable buffer conditions to keep the protein most stable and decrease degradation of
protein, we used to collect only 1 mL of cells, and we decided to vortex cells for 1 min as
the sample amount was very low for sonication or any other lysis instrument. At the end of
the analysis best lysis buffer decided was 50 mM Sodium phosphate buffer with 150 mM
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NaCl, 20% Glycerol, 1 mM EDTA at pH 7.4. Modulating different sonication parameters
and comparing them with the French press method for lysis of 2 g E. coli BL21 DE3
pET28a-WT- hFtnL pGKJE8 cells mixed in 30 mL lysis buffer, it was clear that using
sonicator at 50% amplitude for 50 sec with 10 sec O/N and 30 sec OFF will give us the
best result. Table 3.2 summarizes all the variations that were attempted to overexpress the
protein and make the best protocol for extraction of protein. Figure 3.3 clearly shows the
effect of all the conditions that were decided at the end of small-scale overexpression.
For characterization of pH-sensitivity in hFtnL-E4 structure, it is vital to produce
the protein at a large scale. Our main aim in this part was to have hFtnL-E4 in 24mer form
at a very high concentration. Conditions defined during small-scale overexpression study
was used at a large scale. Although Human L-chain Ferritin does not have a ferroxidase
center, one of the analyses suggested mutation in this protein can disrupt Ferritin function
leading to neurodegenerative disease.33 So we decided to add Ferric Citrate while
overexpression, Although Human L-chain Ferritin does not have a ferroxidase center, one
of the analyses suggested mutation in this protein can disrupt Ferritin function of iron
mineralization, leading to neurodegenerative disease.33 So we decided to add Ferric Citrate
during overexpression and protein extraction, to increase protein folding with significantly
less degradation (15kDa band). FtnL-E4 was overexpressed in E.coli BL21 DE3 pGKJE8
cells using defined condition from small scale analysis with 3 mg/L Ferric citrate, except
0.5mM IPTG was used to induce the protein production. After harvesting, cells were mixed
in Lysis buffer + 1 mg/mL lysozyme. After heating the cell solution at 70°C and sonicating
them, lysate was separated from cells using centrifugation at 16000 RPM for 45 min.
hFtnL-E4 was purified using Affinity chromatography through a nickel column. Two peaks
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were observed during Nickel column purification containing hFtnL-E4 (Figure 3.3 Top).
Chaperone proteins that were used for proper folding were also observed on SDS-PAGE
in the same fractions in which Ferritin was present (Figure 3.3 Botom), as there were bands
observed at 70, 40 and 15 kDa ladder,49 18 mg/mL protein concentration in 2.4 mL solution
was achieved without any precipitation which was further purified using a SEC column.
There was single peak observed corresponding to 24-mer of hFtnL-E4 during SEC
purification. However, chaperone proteins were still present with hFtnL-E4. Moreover,
precipitation was observed while concentrating the protein below 3 mL. Precipitated
protein pellet was separated by centrifugation and then again solubilized in Nickel column
elution buffer, which contained 500mM imidazole. Single peak was observed in SEC
purification of resuspended precipitated protein. Figure 3.5 shows the comparison between
chromatograms of soluble protein, resuspended protein, and Horse spleen apoferritin
(obtained from Sigma). All three peaks have almost similar retention time which meant
that precipitated protein was successfully resuspended in elution buffer, and it is also in
24-mer form. As Ferric Citrate was used during cell growth and overexpression, so there
is a chance that native E. coli Ferritin might be getting overproduced due to which there
were two distinct peaks observed in Nickel column. Two peaks could mean that there could
be one protomer, a mix of hFtnL-E4 and native E. coli Ferritin subunit, and another
protomer that could have only hFTnL-E4 subunit. This was the hypothesis so; next
purification was performed without using Ferric Citrate at any point.
Figure 3.4 Top shows the single peak shifted towards higher Imidazole
concentration which was observed after not using of Ferric Citrate during overexpression.
This confirms that E. coli native Ferritin was getting overexpressed. Shifting of the peak
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towards higher Imidazole concentration was the result of more tight binding of hFtnL-E4
suggesting that there is only His-tagged protein is present. However, during purification of
protein using SEC column two peaks were observed (Figure 3.4 Bottom). Both the peaks
contained hFtnL – E4 which meant that there are two forms of hFtnL-E4 are present. This
was observed for the first time which could be result of not using Ferric Citrate during
extraction. This confirmed that Ferric Citrate helped in proper folding of hFtnL-E4 in
24mer form after cell lysis.
Analyzing many SDS-PAGE gel during all the troubleshooting we observed that
there were three bands that were always present in the same fractions and same thing was
observed when pGkJE8 was co-expressed with hFtnL-GALA6. These observations and
previous literature confirmed that chaperone proteins remain attached to protein which
could be result of incomplete protein folding mechanism. Morales et al. showed that
chaperone proteins could be removed by using Mg-ATP during Nickel column
purification, but this resulted in precipitation of protein while concentrating it14 . Since ATP
is required for the removal of so may be adding extra source energy during overexpression
in growth media could help in completion of folding mechanism by chaperones. So instead
of adding glucose to LB media, Terrific Broth (TB) media was used as it contained glycerol
which could also work as ATP source. At last TB media used for the growth of
overexpressed cells and Ferric Citrate was used during extraction. As hFtnL-E4 was always
eluted after 47% of Elution buffer in linear gradient method. For more detailed purification
protocol refer appendix.
In Final protocol pGKJE8 + pET28a hFtnL-E4 transformed cells were
overexpressed in 1L Tb media with 0.5 mg/mL L-Arabinose, 5 ng/mL Tetracyclin, 50

35

µg/mL Kanamycin, 20 µg/mL Chloramphenicol and 1mM IPTG. Cells were harvested at
6000 RPM for 10 min. Cell pellet was resuspended in Lysis buffer (50 mM Sodium
Phosphate, 150 mM NaCl, 1mM EDTA, 20% Glycerol, 20 mM Imidazole, 1mg/mL
Lysozyme, pH 7.4) and then frozen in -80°C. Frozen cell pellet was liquified at 37°C and
then again diluted to 120 mL using Lysis buffer. 200 µL Ferric citrate was added to
neutralize EDTA and for proper folding of protein. Then cell solution was heated at 70°C
for 15 min. 1mM PMSF was added, and sonication was performed to lyse cells. Lysate was
separated at 16000 RPM for 45 min. HisTrap HP 5 mL column was equilibrated using
washing buffer (20 mM Sodium Phosphate, 500 mM NaCl, 20 mM Imidazole, pH 7.4) and
then Lysate was loaded on the column. Eluted protein obtained after using gradient method
on Nickel column was concentrated to 2.4 mL and 5% glycerol was added before loading
2 mL sample on Superdex 200 Hiload 16/60 column. Samples were observed on 15% SDSPAGE and then solution was concentrated to 2.5 mL. 2 mM hFtnL-E4 was confirmed using
Bradford protein estimation assay. Single peak in chromatograms obtained from both the
columns confirmed formation of properly folded protein (24mer) which can be seen in
Figure 3.6
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Table 3.1 List of sequences designed and there GRAVY score comparison.
No. of
amino

GRAVY

Name

E-helix sequence

acids

score

WT-hFtnL

PEAGLGEYLFERLTLKH

13

-0.594

hFtnL-EALA6 PEAGLAEALAEALAEALAEALAEALAE 23

-0.436

hFtnL-EAQA4 PEAGQAEAQAEAQAEAQAE

15

-0.655

hFtnL_EAQA6 PEAGQAEAQAEAQAEAQAEAQAEAQAE 23

-0.663

hFtnL-E6

PEAGEGEYEFERETLKEAQAEAQAE

21

-0.721

hFtnL-E4

PEAGEGEYEFERETLKEAQAE

17

-0.718
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Table 3.2 Troubleshooting performed during Small-scale overexpression to determine
best conditions to extract protein.
Plasmi
d

pEt
28a+ hFtnL
E4
with
pGKJE
8
(GroE
LGroES
and
dnaKdnaJgrpE).

Overexpressio
n condition

50µg
/mL
Kanamycin,
20µg
/mL
Chlorampheni
col, 0.5mg/mL
L-Arabinose,
20ng/mL
Tetracyclin,
20ᵒC,
overnight, and
1mM IPTG.

Lysis
condition

buffer

Constant

Variable

100mM
NaCl,
5mM
EDTA,
pH 7.4

20- and
50-mM
Sodium
Phospha
te

50 mM
Sodium
Phosphat
e.
Degradati
on
of
protein
observed

50 mM
Sodium
Phospha
te, 5mM
EDTA,
pH 7.4

100,
150, 500
mM, and
1M
Sodium
Phospha
te

150, 500
mM and 1
M
had
same
result.
Degradati
on
observed.
150 mM
NaCl was
used for
further
analysis.

50 mM
Sodium
Phospha
te, 5mM
EDTA,
pH 7.4,
150mM
NaCl

10%,
20%,
50%
Glycerol
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Lysis method

1 mg/mL Lysozyme
and 1 min Vortexing

Best
condition
inferred

20%
Glycerol
was best.
Still
degradati
on
was
observed.

1mg/mL
Lysozy
me

50 mM Sodium
Phosphate,
5mM
EDTA, pH 7.4,
150mM NaCl, 20%
Glycerol

50
mM
Sodium
Phosphate,
pH
7.4,
150mM
NaCl, 20%
Glycerol

1 mM
and 5
mM
EDTA
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Sonicati
on,
French
press,
Freeze
thaw.

Except
sonicatio
n none of
the
technique
was able
to Lyse
cells. So
sonicatio
n
was
further
analyzed

Multiple
conditio
ns
of
Sonicati
on

Sonicatio
n – 50sec,
50%
amplitude
, 10 sec
ON, 30
sec OFF
resulted
least
degradati
on
and
better
extraction
.

1mg/mL Lysozyme
and Sonication –
50sec,
50%
amplitude, 10 sec
ON, 30 sec OFF

1 mM and
5
mM
EDTA
sonicatio
n
had
same
result so,
1
mM
EDTA
was used
as final
condition.

Figure 3.1 A WT-hFtnL, hFtnL-E4, hFtnL-E6 overexpressed in various conditions.
Overexpression Temperature - 37°C, induced using IPTG – 0.1, 0.25,0.5, 1 mM,
Induction time – 4 hours and 6 hours.
WT I-4 0.1- WT-hFtnL induced cells for 4 hours using 0.1 mM IPTG, WT I-4P 0.1 Lysed WT-hFtnL pellet collected after protein extraction, induced for 4 hours using 0.1
mM IPTG, WT I-4S 0.1 – Solublized protein obtained after lysis.
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Figure 3.1 B WT-hFtnL, hFtnL-E4, hFtnL-E6 overexpressed in various conditions.
Overexpression Temperature - 37°C, induced using IPTG – 0.1, 0.25,0.5, 1 mM,
Induction time – 4 hours and 6 hours.
WT I-4 0.1- WT-hFtnL induced cells for 4 hours using 0.1 mM IPTG, WT I-4P 0.1 Lysed WT-hFtnL pellet collected after protein extraction, induced for 4 hours using
0.1 mM IPTG, WT I-4S 0.1 – Solublized protein obtained after lysis.
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Figure 3.2 WT-hFtnL overexpressed in various conditions. Overexpression
Temperature - 20°C, induced using IPTG – 0.1, 0.25,0.5, 1 mM, Induction time – 4
hours and 6 hours.
WT I-4 0.1- WT-hFtnL induced cells for 4 hours using 0.1 mM IPTG, WT I-4P 0.1 Lysed WT-hFtnL pellet, induced for 4 hours using 0.1 mM IPTG, WT I-4S 0.1 –
Solublized protein obtained after lysis.
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hFtnL-E4

Figure 3.3 Chromatogram for Purification of hFtnL-E4 with Ferric Citrate using 5 mL
HisTrap column.
3 mg/L Ferric Citrate is used during protein overexpression. 4 mg/mL Ferric Citrate is
used during Protein extraction.
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Chaperon
e proteins

Chaperone
proteins

Figure 3.4 15% SDS – PAGE of hFtnL-E4 with Ferric Citrate purified using 5 mL
HisTrap column.
3 mg/L Ferric Citrate is used during protein overexpression. 4 mg/mL Ferric Citrate is
used during Protein extraction.
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A

B

Figure 3.5 Purification of hFtnL-E4 without adding Ferric citrate.
A) No peak observed in HisTrap protein purification indicating only single type of
protein being overexpressed.
B) Concentrated protein solution showed 2 peaks of hFtnL-E4 concluding that
addition of Ferric citrate during extraction helps in proper folding of protein.
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A

B

C
Figure 3.6 Comparison between (A) Horse spleen Apoferritin, (B)Soluble hFtnLE4, and (C) resuspended hFtnL-E4.
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Figure 3.7 Final Superdex 200 Hiload 16/60 purification of hFtnL-E4 using
elution buffer.
Elution Buffer – 20 mM Sodium Phosphate buffer, 500 mM NaCl, 500 mM
Imidazole pH 7.4
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CHAPTER 4: FUTURE DIRECTIONS
4.1 EXPRESSION AND PURIFICATION OF OTHER MODIFICATIONS OF
FERRITIN
After many troubleshooting a protocol to extract and purify Ferritin based protein
was formed. WT-hFtnL, hFtnL-E6 is another modification of human light chain ferritin
that was ordered with hFtnL-E4. Moreover, hFtnL-EALN6 is another modification that
was formed by our collaborator Dr. N. Grossoehme. These proteins are embedded in
pET28a plasmid. All these plasmids should be extracted and purified using the finalized
protocol. If results are similar for all the proteins as compared to hFtnL-E4 then we can
generalize this protocol for any human light chain ferritin-based protein.
4.2 IDENTIFICATION OF BEST MODIFICATION
After purified hFtnL-E6, hFtnL-EALN6 is obtained then we need to study the
characteristics of all the modifications. At the end of purification protocol proteins remain
in high concentration of Imidazole (500 mM). There are two contradictory research papers
that showed that Imidazole is good for solubilizing a protein and another shows that it has
inhibitory effect on protein activity.50,51 Keeping both the papers in mind protein when
need to be stored for very long time then buffer having high concentration of Imidazole
should be used. However, disassembling and assembling protein is protein-protein
interaction so to have effective interactions Imidazole should be removed from the solution.
Now the later step in which Imidazole will be removed from the solution might cause
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protein precipitation. At this step if any of the above-mentioned modification do not
precipitate can be considered very soluble is good for further studies.
The buffer exchange step is good step to identify soluble protein but should be
considered secondary method to identify a good modification. The ferritin modification
which shows maximum disassembling and assembling of protein at very short range of pH
change should be the first iterative method to identify the best modification. According to
previous data available on hFtnL-GALA6 disassembling of protein occurs at pH 6 so, if
any ferritin modification that disassembles in pH range 7 – 6 should be considered a better
modification. According to our main aim we are modifying the ferritin to load various
drugs in the nanocage by simply making it pH responsive. Even native ferritin is pH
responsive, it requires very acidic condition to dissociate which most of the therapeutic
drugs cannot withstand. So, any modification that requires smaller change in pH to cause
disassembling and assembling will be best as it will cause less side effect on drug that is
being loaded.
4.3 CHARACTERIZATION OF pH RESPONSIVENESS
hFtnl-E4, hFtnL-E6 and hFtnL-EALN6 extraction and purification completes the
first part of Aim 1. To complete second part of Aim 1, pH responsiveness needs to be
characterized. Table 4.1 shows the molecular weight of 24mer (assembled), monomer, and
dimer (disassembled) form of all three modifications. The techniques that will be used for
characterization are Size Exclusion Chromatography, Circular Dichroic Spectra, and
Dynamic Light Scattering. In case of Size Exclusion chromatography peaks referring to
oligomer state and monomeric or dimeric state should be observed. To initiate
characterization, whatever analytical SEC column will be used first standards needs to be
49

run. Each standard that will be used should be run separately instead of mixing in one
solution since some standards tend to coelute which will cause changes in Ve value and
ultimately give wrong R2 value. Additionally, we do not need to run all the standards as we
just have to analyze assembled and disassembled state so only Thyroglobulin, Apoferritin,
Alcohol dehydrogenase, BSA and Cytochrome C. This step with standards needs to be
repeated till we get R2 = 0.99. To prepare sample, buffer of the protein solution should be
exchanged with Analysis buffer (20 mM Sodium Phosphate buffer pH 7.4, 100 mM NaF).
This step is important as the same sample must be used for all the techniques that will be
used for characterization of pH responsiveness. Additionally, Imidazole and NaCl has very
high absorption value which will cause problem in analyzing the protein using CD and
DLS. Moreover, the concentration required for all three techniques is very less so there
might not be requirement to troubleshoot the buffer condition to get high concentration of
protein in solution. Sample and standard volume for SEC should be decided according to
the manual provided with the column. Concentration of hFtnL-E4, hFtnL-E6 and hFtnLEALN6 should be equal to the concentration of Apo ferritin. Most probably single peak
should be observed which should have retention time between Thyroglobulin and
Apoferritin. Using this data molecular weight of assembled state can be easily determined.
Circular dichroism measures the secondary structure present in protein structure.
According to the hypotheses at pH above 7, E-helix is supposed to form irregular structure
and at pH below 6 E-helix should form α-helix. However, the change in helical structures
for other peptides (A, B, C, D) of protein subunit, while changing pH are not recorded
previously for native ferritin. Previous studies on hFtnL-GALA6 show decrease in overall
α-helical structure when pH was decreased from 7 to 6 and the same sample was used for
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SEC column and it showed peak corresponding to monomeric state of protein.38 So, in our
experimentation with E4, E6, and EALN6 modifications higher irregular structure should
correspond to disassembled state of the protein. CD analysis should be done in Far-UV
range (180 – 280 nm). Jasco CD model J-815 will be used with Spectrocell Inc. 1mm quartz
cuvette. It is recommended to not exceed 0.1 mg/mL for 1mm path length.52 For all the
analysis, conditions should not change. Blank buffer solution should be analyzed first and
then sample should be analyzed after subtracting blank. Scanning speed should be 10
nm/min at 25°C.38 There three most important points to keep in mind firstly, the
concentration of protein should be accurately measured as it will be used in analyzing the
sample on different software. Secondly, consistency very important which include cuvette
size, shape, path length and company. Also, the side of cuvette facing detector and lamp
should be consistent. Third is clarity of sample. Since there is a chance that protein might
get absorbed by 0.22 µm filter the best way to clear the protein solution of any precipitates
is by centrifuging at 13000 RPM for 2 min. After successful analysis, data obtained can be
analyzed using CAPITO software which available online.53
Non-invasiveness of Dynamic Light scattering (DLS) makes it widely accepted
protein characterization technique. DLS in this project will be used to determine molecular
weight and radius of gyration of protein molecule. For the initial experimentation sample
prepared for CD should be used. However, if the good result is not obtained then either the
concentration of protein sample or buffer solution conditions should be troubleshooter.
To analyze disassembled state of protein, protein precipitation needs to be analyzed.
If protein precipitates at pH 6 then pH titration must be done. pH titration is important to
monitor the pH at which protein starts precipitating out. The main reason behind this step
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is to keep the protein in the solution while it is disassembled. Once the lowest pH at which
the protein remains soluble is determined then that pH can be used to make a new buffer.
Then perform buffer exchange of protein sample and again perform all the steps that were
done at pH 7.4.
4.4 STRUCTURAL STUDY
To fully understand the structure X-ray crystallography and Small Angel X-ray
Scattering (SAXS) must be performed. Crystallizing protein will “freeze” the structure
which can be analyzed using X-ray. PDB deposit 2FFX shows the crystal structure of wild
type human light chain ferritin has been published.54 Wang et al. analyzed multiple crystals
in different buffer conditions out of which the conditions out of which 2FFX was published
can be used to analyze new protein modifications. If the published conditions to crystallize
structure do not work efficiently then the course of action will be to give sample to a lab
which has expertise in this technique. Although X-ray crystallography will help in
analyzing structure but analyzing structure in solution is very important. Protein structure
in solution might behave differently which can be analyzed by SAXS. However, SAXS
will be very new technique for our lab so many conditions will need to be troubleshooter
to get best structural data.
4.5 LOADING OF NANOCAGE
Second aim of this project includes loading the Nano cage with doxorubicin. As
our main aim of this project is to develop pH responsive human light chain Ferritin
nanocage which will be able to deliver drug through endocytic pathway we need to load
the new modifications of ferritin with doxorubicin. Loading of doxorubicin on Apo ferritin
(horse spleen) has been tested in previously literature. In this literature they used Rose
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Bengal (RB) which can stimulate disassembling of the protein using low pH and laser
irradiation. The techniques and method published in this paper can be used for loading
doxorubicin on nanocage of novel proteins and can be analyzed in vitro, in vivo in cancer
cells and mouse models.
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Table 4.1 List of proteins and the molecular weight of monomer, dimer, and 24 – mer.

Protein Name

hFtnL-E4

hFtnL-E6

WT-hFtnL

Monomer

21397.89

21797.29

20958.64
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Dimer

24 - mer

42,795.78

513,549.36

43,594.58

523,134.96

41,917.28

503,007.36
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APPENDIX A: OVEREXPRESSION
Protocol
1.

Made sure whether we have E. coli BL21 DE3 cells with pGKJE8 and pET28a
- hFtnL-E4 in -80°C or transformation is required.

2.

After confirmation leave them back in -80°C till the time starter culture.

3.

Two 1L TB media in 4L flask was made. Composition of Large-scale TB
mediaa. TB is a highly enriched medium used for the cultivation of bacteria.
b. 900 mL TB medium contain tryptone 1.2%, yeast extract 2.4%, glycerol
0.5% and 100 mL of 10X TB salt phosphate buffer (89 mM)
c. TB medium:
i. 1.2% tryptone = 12 g/L
ii. 2.4 % yeast extract = 24 g/L
iii. 0.5 % glycerol = 5 g/L
iv. Dissolved tryptone, yeast extract and glycerol in water to a final
volume of 900 ml and autoclave for 15 min at 121°C. Let it cool
down to room temperature before adding the 10X TB salt solution.
v. Made only 250 mL of 10X TB salt solution since only 200 mL will
be used. Here is composition for 1 L 10X TB salt solution 1. 0.17 M KH2PO4 = 23.1 g/L
60

2. 0.72 M K2HPO4 = 125.4 g/L
vi. Dissolved 5.8 g KH2PO4 and 31.35 g K2HPO4 in water to a final
volume of 250 mL and autoclaved for 15 min at 121°C.
d. Kept the autoclaved 10X TB salt solution at room temperature to cool down.
Salts tend degrade the media at high temperature. So, waited till next day to
make sure that all the solutions have cooled down to room temperature.
4.

Terrific Broth media will be used for the cell growth. For the starter culture
stock TB media was used. 20mL (1:50 of volume of large culture) starter culture
was added to 50 mL falcon tube.

5.

Made two starter culture for 2 Large-scale culture. Composition of starter
culture
a. 20 mL TB media from stock bottle in 50 mL falcon tube.
b. Kanamycin – 50 µg/mL from 50 mg/mL stock solution in 20 mL starter
media.
c. Chloramphenicol - 20 µg/mL from 20 mg/mL stock solution in 20 mL
starter media.

6.

After making above solution take out the frozen cells described in first step and
used 200 µL tip to scratch the top of frozen cells and mixed the cells in starter
culture by shaking the tip in the solution. This step was performed very quickly
before defrosting of the stock cells and as then the cells were stored back in 80°C quickly.

7.

Incubated the starter culture in 37°C water bath shaker for overnight.
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APPENDIX B: PROTEIN OVEREXPRESSION
1.

Mixed 100 mL of 10x TB salt in TB medium. Then kept the 4L flasks in floor
shaker and set the temperature to 37°C. Do not press start button otherwise it will
start shaking the flask. At this point you just need to maintain temperature of the
flask no shaking is required.

2.

Now make the solution of antibiotics and chaperone inducers. Composition for 1L
media -:
a. Kanamycin – 50 µg/mL from 50 mg/mL stock solution i.e., 1 mL of stock solution.
If there is not enough stock solution, then make 50 mg/mL stock solution in ddH2O.
b. Chloramphenicol - 20 µg/mL from 20mg/mL stock solution i.e., 1 mL of stock
solution. If there is not enough stock solution, then make 20 mg/mL stock solution
in 100% Ethanol.
c. L-Arabinose - you need 0.5 mg/mL in 1L media from 200 mg/mL stock solution.
So, make 2.5 mL stock solution.
d. Tetracycline - 5 ng/mL in 1 L media. concentration of 10 μg/mL. Tetracycline stock
solution is already in -20°C.
e. Added all the above solutions in 2.5 mL L-arabinose stock solution.

3.

Poured above solution and 20 mL starter culture to Large-scale cultures and started
shaking the cultures at 200 RPM.
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4.

Checked OD600 after 2 hours. Used TB media as blank. If the OD600 is around
0.5 then lower the temperature to 20°C. After 30 mins add 1mM IPTG and then
leave it overnight.
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APPENDIX C: CELL HARVESTING
1. Transfer the media to 1 L centrifuge bottles. Equalize the weight and then
centrifuge the bottles at 6000 RPM for 10 min at 4°C.
2. Remove the supernatant and transfer the pellet to 50 mL Falcon tube.
3. Add 15 mL Lysis solution.
4. Make 1 mg/mL Lysozyme solution using lysis buffer according to the total volume
of cell solution. For example, if the total cell solution is 30 mL then measure 31 mg
Lysozyme. Mix it with 0.8 mL Lysis solution. Make up the volume to 1 mL and
then transfer this solution to cell solution. Do not mix Lysozyme in water always
use Lysis solution.
5. Vortex the cell solution to make sure that all the cells have dissolved in the solution
and there is no lumps present.
6. Freeze the cells at -80°C.
7. Make sure you have all the buffers available for extraction purification.
a. Lysis Buffer - 50 mM Sodium Phosphate, 150 mM NaCl, 1mM EDTA, 20%
Glycerol, 20 mM Imidazole, pH 7.4
b. Binding/Washing Buffer - 20 mM Sodium Phosphate, 500 mM NaCl, 20
mM Imidazole, pH 7.4
c. Elution Buffer and gel filtration buffer - 20 mM Sodium Phosphate, 500
mM NaCl, 500 mM Imidazole, pH 7.4
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APPENDIX D: EXTRACTION AND PURIFICATION
1. Take out the cells keep them in water bath shaker to defrost. Keep it shaking for
faster defrosting. Also switch on 70°C water bath heater so that it is hot up by the
time you need it.
2. Once solution liquifies add some more lysis solution to make the volume to a level
so that you can divide whole solution in 4 equal volumes. So let's say if the volume
is 30 mL then I will increase it to 40 mL by adding Lysis buffer. Then divide the
solution in 4 equal parts.
3. At this point you must have four 50 mL falcon tubes with 10 mL cell solution in it.
These solutions are still very concentrated, so you need to dilute the solution. I
would increase the total volume to 30 mL in each falcon.
4. Adding Lysis solution will decrease the lysozyme concentration too. So, you need
to add 1 mg/mL Lysozyme again in each falcon tube. Follow exactly same
procedure as described in DAY 3 step 4.
5. Keep the tubes in 37°C water bath shaker for 30 min.
6. Add 200 µL Ferric citrate solution in each falcon. Then keep them in 70°C water
bath heater for 10 min.
7. Make 1 mL of 200 mM PMSF solution in Isopropanol. Then add PMSF to each
falcon tube to final concentration of 1 mM.
8. Switch on the centrifuge. Fix the small rotor and then leave it to cool down to 4°C.
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9. Transfer all the solution in one beaker for sonication. Sonication Method - 50%
amplitude, 50 sec sonication, 10 sec ON and 30 sec OFF.
10. After sonication centrifuge the solution using centrifuge tube at 16000 RPM for 45
min.
11. Attach the Nickel column and start the purification procedure. Refer Table D1 for
the purification method.
12. Transfer the supernatant to a beaker carefully without disturbing the pellet.
13. Drop the sample tube in the Lysate beaker. At this point procedure must have
stopped on its own after elution is complete. Open the sample port to remove air
from the tube using syringe. Do not throw the lysate solution while removing air.
Add it back to the solution in beaker. Click on the continue to start the purification.
14. Collect 20 µL sample from the fractions and run SDS-PAGE to confirm the
fractions containing hFTnL-EALN6. Do not forget to run Lysed cells, Lysate and
Flowthrough.
15. Once you confirmed the fractions that contain hFtnL-EALA6 collect those fractions
in one Falcon tube.
16. Start concentrating the protein to 2.4 mL. You need to centrifuge concentrating
tubes at 4000 RPM for 20 min. This has to be repeated as many times required to
bring down the solution collected from fraction to 2.4 mL.
17. Now do the Bradford assay:
a. For standards, mix solutions according to the Table D2.
b. Make these solutions in 1.5 mL microcentrifuge tubes.
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c. Now make your samples. For sample I will first check the color by mixing
2 µL in 798 µL and then add 200 µL Bradford. If the solution turns very
dark blue compared to standard no. 6, then you need to do more dilution.
i. To prepare more diluted sample mix 2 µL of protein sample in 1000
µL ddH2O this solution has dilution factor = 500. Now take 10 µL
and mix it in 790 µL ddH2O and add 200 µL Bradford. So, your
final solution for Bradford will have DF = 50,000. Calculation 1. DF = (1000/2) × (1000/10) = 50,000
d. Check the OD of standards first and then unknown sample. R2 should be
near 0.99.
18. 5% of glycerol should be in the final concentrated protein. (If the sample is 2.4 mL
then 5% of that should be glycerol which means adding 120 uL of 100% glycerol)
19. Attach a Superdex 200 16/60 column and start the purification procedure.
a. Buffer A will be the elution buffer that was use in the Nickel column. Buffer
B will be ddH20 filtered and autoclaved. Buffer C is 20% ethanol filtered.
b. Before loading the concentrated protein, wash the sample (injection) loop
with ddH20 twice, then elution buffer, and finally insert air into it until you
see the air bubble.
c. Loading the concentrated protein, watch out that the air bubble has been
fully removed and you can see a tiny part of the sample. It should not be too
out as that is lost of protein.
d. Protocol for purification using Superdex 200 Hiload 16/60 is mentioned in
Table D3.
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Table D.1 HisTrap FF 5mL Column Purification. Buffer A – Binding/Washing Buffer,
Buffer B – Elution Buffer
Method Step

Flowrate

Column Wash

Volume

Solution

10 CV

Flitered dH2O
Buffer A

Equilibration

5 CV

Buffer B
Buffer A

Washing

10 CV
5 mL/min

Elution (Gradient)

Buffer A
Buffer A 100 % à 0

20 CV

%
Buffer

B

0%

à

100%
Column Wash

Storage

2 mL/min

5 CV

Buffer A

10 CV

Flitered dH2O

5 CV
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Filtered
Ethanol

20%

Table D.2 Standard preparation for Bradford Assay.
S. no.

ddH2O (µL)

BSA (µL)

Bradford (µL)

Concentration (mg/mL)

Blank

800

0

200

0.000

1

800

0

200

0.000

2

798

2

200

0.002

3

796

4

200

0.004

4

794

6

200

0.006

5

792

8

200

0.008

6

790

10

200

0.010
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Table D.3 Superdex 200 Hiload 16/60 purification method
Method

Flowrate

Volume (Column Solution
Volume = CV)

Column Wash
Equilibration
Elution
Column Wash
Storage

2 CV
1 mL/min

1.5 CV
1 CV
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Filtered dH2O
Elution Buffer
Elution Buffer
Filtered dH2O
20% Ethanol

